Hematologic Malignancies

Share

Program Content

Activities

  • Multiple Myeloma
    Conference to Clinic: Multiple Myeloma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 16, 2023

  • Conference to Clinic: Leukemias
    Conference to Clinic: Leukemias
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 16, 2023

  • ASCO 2023: Lymphomas and CLL
    Conference to Clinic: Lymphomas and CLL/SLL
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 16, 2023

    Expires: June 15, 2024

  • Conference to Clinic: Hematologic Malignancies
    Conference to Clinic: Expert Analysis of the Top Hematologic Malignancies Abstracts From the 2023 Oncology Meeting in Chicago
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 29, 2023

    Expires: June 28, 2024

  • ASCO 2023: Hematologic Malignancies
    Key Studies in Hematologic Malignancies: Independent Conference Coverage of the 2023 ASCO Annual Meeting
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 25, 2023

    Expires: August 24, 2024

Activities

Glofitamab in R/R LBCL
Extended Follow-up and Landmark Analyses From Pivotal Phase II Trial of Glofitamab in R/R LBCL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2023

COMMANDS
COMMANDS: Luspatercept vs Epoetin alfa for ESA-Naive Transfusion-Dependent Lower-Risk MDS
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2023

IMerge
IMerge: Phase III Trial of Imetelstat vs Placebo for Transfusion-Dependent Lower-Risk MDS Relapsed/Refractory to ESAs
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2023

Elranatamab After BCMA Therapy in R/R MM
Elranatamab Monotherapy for R/R MM After Previous BCMA-Directed Therapy: Pooled Analysis of MagnetisMM Studies
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2023

JACKPOT8
JACKPOT8 Part B: Pivotal Phase II Study of Golidocitinib, a JAK1-Selective Inhibitor, in Relapsed/Refractory PTCL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

EPCORE NHL-1 Update
EPCORE NHL-1 Update: Pivotal Phase I/II Trial of Epcoritamab in Patients With R/R B-Cell NHL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

KEYNOTE-667
KEYNOTE-667 High-Risk Group Update: Pembrolizumab + COPDAC-28 Consolidation in Children and AYA cHL
Capsule Summary
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

BRUIN 2-Yr Update
BRUIN 2-Yr Update: Phase I/II Trial Evaluating Pirtobrutinib in Covalent BTKi–Treated MCL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

Phase I PHE885 CAR T-Cell
Phase I: BCMA-Targeted PHE885 CAR T-Cell Therapy With Rapid Manufacturing Time for R/R Multiple Myeloma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

MajesTEC-1 Update: Teclistamab in R/R MM
MajesTEC-1 Update: Phase I/II Study of Teclistamab in Patients With R/R MM
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

CPX-351 vs 7+3: Cardiotoxicity
Cardiotoxicity of CPX-351 vs 7+3 in Previously Untreated High-Risk or Secondary AML: Post Hoc Analysis of a Pivotal Phase III Trial
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

CARTITUDE-1 Update
CARTITUDE-1 Update: Phase I/II Trial of Ciltacabtagene Autoleucel for Heavily Pretreated Relapsed/Refractory Multiple Myeloma
Capsule Summary
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

Alliance A041703
Alliance A041703: Phase II Trial of Inotuzumab Ozogamicin Induction Followed by Blinatumomab Consolidation for Older Adults With Newly Diagnosed Ph-Negative, CD22-Positive B-ALL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 12, 2023

TRANSCEND CLL 004
TRANSCEND CLL 004: Phase I/II Trial of Lisocabtagene Maraleucel for Relapsed/Refractory CLL/SLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 12, 2023

SWOG S1826
SWOG S1826: Phase III Trial of Nivolumab + AVD vs Brentuximab Vedotin + AVD for Newly Diagnosed Advanced cHL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 12, 2023

CARTITUDE-4 With Cilta-Cel vs SoC
CARTITUDE-4: Phase III Trial of Ciltacabtagene Autoleucel vs SoC for Lenalidomide-Refractory Multiple Myeloma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 12, 2023

Faculty

cover img faculity

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

cover img faculity

Jeffrey P. Sharman, MD

Medical Director of Hematology Research
Sarah Cannon at Willamette Valley Cancer Institute
Eugene, Oregon

cover img faculity

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

 Supported by educational grants from AbbVie, Geron, Jazz Pharmaceuticals, Lilly, Merck Sharp & Dohme Corp., and Novartis.

AbbVie

Geron

Jazz Pharmaceuticals

Lilly

Merck Sharp & Dohme Corp.

Novartis